West Pharmaceutical Services, Inc. $WST Stake Decreased by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 7.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,465,858 shares of the medical instruments supplier’s stock after selling 196,177 shares during the period. Bank of New York Mellon Corp’s holdings in West Pharmaceutical Services were worth $618,043,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC grew its stake in shares of West Pharmaceutical Services by 10.8% in the fourth quarter. Darwin Wealth Management LLC now owns 410 shares of the medical instruments supplier’s stock worth $113,000 after purchasing an additional 40 shares in the last quarter. IFM Investors Pty Ltd raised its stake in shares of West Pharmaceutical Services by 0.3% during the first quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock valued at $3,452,000 after purchasing an additional 43 shares in the last quarter. Aptus Capital Advisors LLC lifted its holdings in West Pharmaceutical Services by 5.5% in the fourth quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock worth $249,000 after purchasing an additional 47 shares during the period. Benjamin Edwards Inc. lifted its holdings in West Pharmaceutical Services by 1.7% in the second quarter. Benjamin Edwards Inc. now owns 3,021 shares of the medical instruments supplier’s stock worth $661,000 after purchasing an additional 50 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in West Pharmaceutical Services by 4.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,207 shares of the medical instruments supplier’s stock valued at $334,000 after buying an additional 53 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Insider Buying and Selling at West Pharmaceutical Services

In related news, CAO Chad Winters sold 896 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares in the company, valued at $457,920.41. This trade represents a 37.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president directly owned 16,828 shares in the company, valued at $5,135,905.60. This represents a 14.34% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Price Performance

NYSE WST opened at $362.08 on Friday. West Pharmaceutical Services, Inc. has a 1 year low of $206.80 and a 1 year high of $367.66. The business’s fifty day moving average is $332.06 and its two-hundred day moving average is $284.28. The stock has a market capitalization of $25.58 billion, a P/E ratio of 48.41, a P/E/G ratio of 2.91 and a beta of 1.16. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.45. The business had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.67 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The company’s revenue was up 21.0% compared to the same quarter last year. During the same period last year, the company posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, research analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

WST has been the topic of several research analyst reports. Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Wolfe Research began coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They issued an “outperform” rating and a $375.00 price objective for the company. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Stephens reissued an “overweight” rating and set a $360.00 target price on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Finally, Morgan Stanley upped their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, West Pharmaceutical Services currently has a consensus rating of “Buy” and an average target price of $363.17.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.